| | Germany
Indication: No information available.
Brand name: Ablify, Abilitat, Arpizole, and Arip-MT.
Regulatory status: Recommended for approval in schizophrenia by CPMP. No information available yet on potential bipolar filings.
Launch date: No information available.Committee for Proprietary Medicinal Products
| | | |
